Roflumilast tablets (Roflumilast)-DALIRESP effects and efficacy

Roflumilast tablets (Roflumilast)-DALIRESP is a selective phosphodiesterase 4 (PDE4) inhibitor, mainly used to treat chronic obstructive pulmonary disease (COPD; COPD). Its active metabolite, roflumilast N-oxide, works together with roflumilast itself to effectively inhibit PDE4. PDE4 is the main cyclic-3′,5′-adenosine monophosphate (cAMP) metabolic enzyme in lung tissue, and its role is to reduce intracellular cAMP levels.

In the pathological process of chronic obstructive pulmonary disease, inflammatory response is one of the key factors leading to aggravation of the disease and worsening of symptoms. By inhibitingPDE4, roflumilast increases the accumulation of intracellular cAMP, a process thought to be its primary therapeutic mechanism. The increase in cAMP helps regulate a variety of cellular functions, including the relaxation of smooth muscles, activation of immune cells, and the release of inflammatory mediators, thereby reducing the inflammatory response in the lungs.

Although the specific mechanism of action of roflumilast in COPD patients is not yet fully understood, studies have shown that it helps improve patients’ respiratory function and reduce the incidence of acute exacerbations by reducing the inflammatory response in the lungs. This anti-inflammatory effect is particularly helpful for COPD patients with chronic bronchitis, as their condition is often accompanied by a more pronounced inflammatory response.

In addition, the use of roflumilast can improve patients' quality of life. While receiving treatment, many patients report relief from dyspnea and an improvement in their ability to carry out daily activities. Through continued use, roflumilast can not only stabilize the condition, but also reduce the risk of hospitalization to a certain extent and reduce medical costs.

In short, roflumilast tablets, as a selectivePDE4 inhibitor, can effectively reduce the inflammatory response in patients with chronic obstructive pulmonary disease by increasing intracellular cAMP levels in the lungs, thereby improving their symptoms and quality of life. This makes roflumilast an important drug option in the treatment of COPD, providing patients with better treatment prospects.

Reference materials:https://go.drugbank.com/drugs/DB01656